Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons

Journal of Physiology

Volumn 575, Issue 2, 2006, Pages 397-402

  Jacobs, F M J ^a   Smits, S M ^a   Hornman, K J M ^a   Burbach, J P H ^a   Smidt, M P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PITX3;

BRAIN DEVELOPMENT; CELL MIGRATION; DEVELOPMENTAL GENETICS; DIENCEPHALON; DOPAMINERGIC NERVE CELL; DRUG TARGETING; EMBRYO PATTERN FORMATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE TRANSFER; GENETIC HETEROGENEITY; HUMAN; IN VIVO GENE TRANSFER; KNOCKOUT GENE; MOLECULAR GENETICS; NERVE CELL DIFFERENTIATION; NERVE GROWTH; NEURAL TUBE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REGULATOR GENE; REVIEW; SCHIZOPHRENIA; TRANSGENICS; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; DOPAMINERGIC SYSTEM; GENE TARGETING; HIGH THROUGHPUT SCREENING; MESODIENCEPHALIC DOPAMINERGIC SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

ANIMALS; CELL DIFFERENTIATION; DIENCEPHALON; DOPAMINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE TRANSFER TECHNIQUES; HUMANS; MESENCEPHALON; MICE; MICE, KNOCKOUT; NEURONS; PARKINSON DISEASE; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 33747697763     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.113233     Document Type: Review

References (53)

1. Althini S, Bengtsson H, Usoskin D, Söderström S, Kylberg A, Lindqvist E, Chuva de Sousa Lopes S, Olson L, Lindeberg J & Ebendal T (2003). Normal nigrostriatal innervation but dopamine dysfunction in mice carrying hypomorphic tyrosine hydroxylase alleles. J Neurosci Res 72, 444-453.
2. Andersson E, Jensen JB, Parmar M, Guillemot F & Björklund A (2006a). Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2. Development 133, 507-516.
3. Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, Robert B, Perlmann T & Ericson J (2006b). Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124, 393-405.
4. Blum M (1998). A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat Neurosci 1, 374-377.
5. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L & Isacson O (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14, 1709-1725.
6. Das PM, Ramachandran K, vanWert J & Singal R (2004). Chromatin immunoprecipitation assay. Biotechniques 37, 961-969.
7. Farkas LM, Dünker N, Roussa E, Unsicker K & Krieglstein K (2003). Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J Neurosci 23, 5178-5186.
8. Grace AA, Gerfen CR & Aston-Jones G (1998). Catecholamines in the central nervous system. Overview. Adv Pharmacol 42, 655-670.
9. Greene JG, Dingledine R & Greenamyre JT (2005). Gene expression profiling of rat midbrain dopamine neurons: Implications for selective vulnerability in parkinsonism. Neurobiol Dis 18, 19-31.
10. Grimm J, Mueller A, Hefti F & Rosenthal A (2004). Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A 101, 13891-13896.
11. Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P & Youdim MBH (2004). Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111, 1543-1573.
12. Hauser MA, Li Y-J, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM & Vance JM (2005). Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62, 917-921.
13. Hearnes JM, Mays DJ, Schavolt KL, Tang L, Jiang X & Pietenpol JA (2005). Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol 25, 10148-10158.
14. Hermanson E, Borgius L, Bergsland M, Joodmardi E & Perlmann T (2006). Neuropilin1 is a direct downstream target of Nurr1 in the developing brain stem. J Neurochem 97, 1403-1411.
15. Hirsch E, Graybiel AM & Agid YA (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
16. Hoheisel JD (2006). Microarray technology: Beyond transcript profiling and genotype analysis. Nat Rev Genet 7, 200-210.
17. Hwang D-Y, Ardayfio P, Kang UJ, Semina EV & Kim K-S (2003). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 114, 123-131.
18. Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL, Fodor SPA & Gingeras TR (2002). Large-scale transcriptional activity in chromosomes 21 and 22. Science 296, 916-919.
19. Kim TH, Barrera LO, Qu C, Calcar SV, Trinklein ND, Cooper SJ, Luna RM, Glass CK, Rosenfeld MG, Myers RM & Ren B (2005a). Direct isolation and identification of promoters in the human genome. Genome Res 15, 830-839.
20. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA, Wu Y, Green RD & Ren B (2005b). A high-resolution map of active promoters in the human genome. Nature 436, 876-880.
21. Kirmizis A & Farnham PJ (2004). Genomic approaches that aid in the identification of transcription factor target genes. Exp Biol Med (Maywood) 229, 705-721.
22. Krieglstein K (2004). Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res 318, 73-80.
23. Krieglstein K, Suter-Crazzolara C, Hötten G, Pohl J & Unsicker K (1995). Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J Neurosci Res 42, 724-732.
24. Langston J, Langston E & Irwin I (1984). MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurol Scand Suppl 100, 49-54.
25. Mandel S, Grünblatt E, Maor G & Youdim MBH (2002). Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27, 1231-1243.
26. Marín F, Herrero M-T, Vyas S & Puelles L (2005). Ontogeny of tyrosine hydroxylase mRNA expression in mid- and forebrain: Neuromeric pattern and novel positive regions. Dev Dyn 234, 709-717.
27. Miller RM, Callahan LM, Casaceli C, Chen L, Kiser GL, Chui B, Kaysser-Kranich TM, Sendera TJ, Palaniappan C & Federoff HJ (2004). Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J Neurosci 24, 7445-7454.
28. Miller RM & Federoff HJ (2005). Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 11, 539-549.
29. Nunes I, Tovmasian LT, Silva RM, Burke RE & Goff SP (2003). Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 100, 4245-4250.
30. Perlmann T & Wallén-Mackenzie A (2004). Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res 318, 45-52.
31. Petersen S & Petersen I (2003). Expression profiling of lung cancer based on suppression subtraction hybridization (SSH). Meth Mol Med 75, 189-207.
32. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS & Rosenthal A (1994). TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 13, 1245-1252.
33. Prakash N, Brodski C, Naserke T, Puelles E, Gogoi R, Hall A, Panhuysen M, Echevarria D, Sussel L, Weisenhorn DMV, Martinez S, Arenas E, Simeone A & Wurst W (2006). A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 133, 89-98.
34. Prakash N & Wurst W (2004). Specification of midbrain territory. Cell Tissue Res 318, 5-14.
35. Puelles E, Acampora D, Lacroix E, Signore M, Annino A, Tuorto F, Filosa S, Corte G, Wurst W, Ang S-L & Simeone A (2003). Otx dose-dependent integrated control of antero-posterior and dorso-ventral patterning of midbrain. Nat Neurosci 6, 453-460.
36. Puelles E, Annino A, Tuorto F, Usiello A, Acampora D, Czerny T, Brodski C, Ang S-L, Wurst W & Simeone A (2004). Otx2 regulates the extent, identity and fate of neuronal progenitor domains in the ventral midbrain. Development 131, 2037-2048.
37. Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, Hannett N, Kanin E, Volkert TL, Wilson CJ, Bell SP & Young RA (2000). Genome-wide location and function of DNA binding proteins. Science 290, 2306-2309.
38. Roussa E & Krieglstein K (2004). Induction and specification of midbrain dopaminergic cells: Focus on SHH, FGF8, and TGF-beta. Cell Tissue Res 318, 23-33.
39. Simon HH, Thuret S & Alberi L (2004). Midbrain dopaminergic neurons: control of their cell fate by the engrailed transcription factors. Cell Tissue Res 318, 53-61.
40. Smidt M, Asbreuk C, Cox J, Chen H, Johnson R & Burbach J (2000). A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci 3, 337-341.
41. Smidt MP, Smits SM, Bouwmeester H, Hamers FPT, van der Linden AJA, Hellemons AJCGM, Graw J & Burbach JPH (2004a). Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131, 1145-1155.
42. Smidt MP, Smits SM & Burbach JPH (2004b). Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra. Cell Tissue Res 318, 35-43.
43. Smidt M, van Schaick H, Lanctôt C, Tremblay J, Cox J, van der Kleij A, Wolterink G, Drouin J & Burbach J (1997). A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc Natl Acad Sci U S A 94, 13305-13310.
44. Smits SM, Burbach JPH & Smidt MP (2006). Developmental origin and fate of meso-diencephalic dopamine neurons. Prog Neurobiol 78, 1-16.
45. Smits SM, Mathon DS, Burbach JPH, Ramakers GMJ & Smidt MP (2005). Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system. Mol Cell Neurosci 30, 352-363.
46. Smits SM, van der Nobelen S, Hornman KJM, von Oerthel L, Burbach JPH & Smidt MP (2005). Signalling through phospholipase C beta 4 is not essential for midbrain dopaminergic neuron survival. Neuroscience 136, 171-179.
47. Tabata H & Nakajima K (2001). Efficient in utero gene transfer system to the developing mouse brain using electroporation: visualization of neuronal migration in the developing cortex. Neuroscience 103, 865-872.
48. Ungerstedt U, Ljungberg T & Steg G (1974). Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 5, 421-426.
49. Vernay B, Koch M, Vaccarino F, Briscoe J, Simeone A, Kageyama R & Ang S-L (2005). Otx2 regulates subtype specification and neurogenesis in the midbrain. J Neurosci 25, 4856-4867.
50. Weinmann AS, Yan PS, Oberley MJ, Huang TH-M & Farnham PJ (2002). Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 16, 235-244.
51. Yasugi S & Nakamura H (2000). Gene transfer into chicken embryos as an effective system of analysis in developmental biology. Dev Growth Differ 42, 195-197.
52. Yoo MS, Kawamata H, Kim DJ, Chun HS & Son JH (2004). Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons. Neurochem Res 29, 1223-1234.
53. Zhao S, Maxwell S, Jimenez-Beristain A, Vives J, Kuehner E, Zhao J, O'Brien C, de Felipe C, Semina E & Li M (2004). Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. Eur J Neurosci 19, 1133-1140.